June 25, 2020 / 5:36 AM / 19 days ago

BRIEF-Geneuro Enrolls First Patient In Temelimab Phase 2 Multiple Sclerosis Trial

June 25 (Reuters) - Geneuro SA:

* GENEURO ENROLLS FIRST PATIENT IN TEMELIMAB PHASE 2 MULTIPLE SCLEROSIS TRIAL IN COLLABORATION WITH THE KAROLINSKA INSTITUTET’S ACADEMIC SPECIALIST CENTER (ASC)

* GENEURO SA - ONE-YEAR SINGLE CENTER TRIAL IS PLANNED TO ENROL 40 PATIENTS WHOSE DISABILITY PROGRESSES WITHOUT RELAPSES, KEY UNMET MEDICAL NEED IN MULTIPLE SCLEROSIS

* GENEURO SA - START OF THIS PHASE 2 TRIAL HAD BEEN POSTPONED DUE TO COVID-19 PANDEMIC

* GENEURO SA - TRIAL RESUMED PROMPTLY AFTER SITUATION ALLOWED, AND RESULTS REMAIN EXPECTED IN H2 2021

* GENEURO SA - THANKS TO KAROLINSKA INSTITUTET, TRIAL RESUMED PROMPTLY AFTER SITUATION ALLOWED, AND RESULTS REMAIN EXPECTED IN SECOND HALF OF 2021 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below